No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

No­var­tis faced a set­back in its am­bi­tion to ex­pand its block­buster drug Cosen­tyx and com­pete in an au­toim­mune con­di­tion with prod­ucts from Roche and Ab­b­Vie …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER